As of 2024-09-19, the Intrinsic Value of United Therapeutics Corp (UTHR) is
415.57 USD. This UTHR valuation is based on the model Discounted Cash Flows (Growth Exit 5Y).
With the current market price of 342.59 USD, the upside of United Therapeutics Corp is
21.30%.
The range of the Intrinsic Value is 318.29 - 624.94 USD
415.57 USD
Intrinsic Value
UTHR Intrinsic Value - Valuation Summary
|
Range |
Selected |
Upside |
| a |
| DCF (Growth 5y) |
318.29 - 624.94 |
415.57 |
21.3% |
| DCF (Growth 10y) |
399.67 - 764.88 |
516.46 |
50.8% |
| DCF (EBITDA 5y) |
536.35 - 800.96 |
628.21 |
83.4% |
| DCF (EBITDA 10y) |
604.26 - 952.89 |
728.85 |
112.7% |
| Fair Value |
600.92 - 600.92 |
600.92 |
75.41% |
| P/E |
540.10 - 1,138.39 |
734.48 |
114.4% |
| EV/EBITDA |
476.86 - 982.68 |
684.51 |
99.8% |
| EPV |
174.13 - 232.57 |
203.35 |
-40.6% |
| DDM - Stable |
188.11 - 516.11 |
352.11 |
2.8% |
| DDM - Multi |
245.74 - 532.74 |
337.28 |
-1.5% |
UTHR Intrinsic Value - Key Valuation Metrics
| Market Cap (mil) |
15,241.83 |
| Beta |
0.26 |
| Outstanding shares (mil) |
44.49 |
| Enterprise Value (mil) |
14,386.13 |
| Market risk premium |
4.60% |
| Cost of Equity |
8.57% |
| Cost of Debt |
4.25% |
| WACC |
8.33% |